

B1
Cont 22. A composition for use in treating an HIV infection in a patient, said composition comprising an amount of an anti-HIV D-nucleoside compound in combination with an amount of the L-nucleoside compound β -L-2'-deoxy-3'-thiacytidine or a pharmaceutically acceptable salt thereof.

23. A composition of claim 20, wherein said 2',3'-dideoxy nucleoside is selected from AZT, 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-dideoxythymidine, 2',3'-dideoxy-2',3'-didehydrothymidine, 2',3'-dideoxy-2',3'-didehydrocytidine and mixtures thereof.

24. A composition according to claim 23, wherein said nucleoside compound is AZT.

25. A composition according to claim 23, wherein said nucleoside compound is 2',3'-dideoxycytidine.

26. A composition according to claim 23, wherein said nucleoside compound is 2',3'-dideoxyadenosine.

27. A composition according to claim 23, wherein said nucleoside compound is 2',3'-dideoxyinosine.

28. A composition according to claim 23, wherein said nucleoside compound is 2',3'-dideoxythymidine.

29. A composition according to claim 23, wherein said nucleoside compound is 2',3'-dideoxy-2',3'-didehydrothymidine.

30. A composition according to claim 23, wherein said nucleoside compound is 2',3'-dideoxy-2',3'-didehydrocytidine.

B1
Cont
31. A composition according to claim 23, wherein said nucleoside compound is AZT, 2',3'-dideoxycytidine, 2',3'-dideoxyinosine, or mixtures thereof.

Sub
C1
32. A composition of claim 21, wherein said 2',3'-dideoxy nucleoside is selected from AZT, 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-dideoxythymidine, 2',3'-dideoxy-2',3'-didehydrothymidine, 2',3'-dideoxy-2',3'-didehydrocytidine and mixtures thereof.

33. A composition according to claim 32, wherein said nucleoside compound is AZT.

34. A composition according to claim 32, wherein said nucleoside compound is 2',3'-dideoxycytidine.

35. A composition according to claim 32, wherein said nucleoside compound is 2',3'-dideoxyadenosine.

36. A composition according to claim 32, wherein said nucleoside compound is 2',3'-dideoxyinosine.

37. A composition according to claim 32, wherein said nucleoside compound is 2',3'-dideoxythymidine.

38. A composition according to claim 32, wherein said nucleoside compound is 2',3'-dideoxy-2',3'-didehydrothymidine.

39. A composition according to claim 32, wherein said nucleoside compound is 2',3'-dideoxy-2',3'-didehydrocytidine.

40. A composition according to claim 32, wherein said nucleoside compound is AZT, 2',3'-dideoxycytidine, 2',3'-dideoxyinosine, or mixtures thereof.

B/
Unit
Sub
C2

41. A composition of claim 22, wherein said 2',3'-dideoxy nucleoside is selected from AZT, 2',3'-dideoxycytidine, 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, 2',3'-dideoxythymidine, 2',3'-dideoxy-2',3'-didehydrothymidine, 2',3'-dideoxy-2',3'-didehydrocytidine and mixtures thereof.

42. A composition according to claim 41, wherein said nucleoside compound is AZT.

43. A composition according to claim 41, wherein said nucleoside compound is 2',3'-dideoxycytidine.

44. A composition according to claim 41, wherein said nucleoside compound is 2',3'-dideoxyadenosine.

45. A composition according to claim 41, wherein said nucleoside compound is 2',3'-dideoxyinosine.

46. A composition according to claim 41, wherein said nucleoside compound is 2',3'-dideoxythymidine.

47. A composition according to claim 41, wherein said nucleoside compound is 2',3'-dideoxy-2',3'-didehydrothymidine.

48. A composition according to claim 41, wherein said nucleoside compound is 2',3'-dideoxy-2',3'-didehydrocytidine.

49. A composition according to claim 41, wherein said nucleoside compound is AZT, 2',3'-dideoxycytidine, 2',3'-dideoxyinosine, or mixtures thereof.

B
Cont

50. A composition according to claim 20, wherein said composition contains 1-1500 mg of said compound (-)-(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof.

51. A composition according to claim 50, wherein said composition contains 20-1000 mg of said compound (-)-(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof.

52. A composition according to claim 51, wherein said composition contains 50-700 mg of said compound (-)-(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof.

53. A composition according to claim 21, wherein said composition contains 1-1500 mg of said compound (-)-(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof.

54. A composition according to claim 53, wherein said composition contains 20-1000 mg of said compound (-)-(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof.

55. A composition according to claim 54, wherein said composition contains 50-700 mg of said compound (-)-(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one or a pharmaceutically acceptable salt thereof.

56. A composition according to claim 22, wherein said composition contains 1-1500 mg of said compound β -L-2'-deoxy-3'-thiacytidine or a pharmaceutically acceptable salt thereof.

57. A composition according to claim 56, wherein said composition contains 20-1000 mg of said compound β -L-2'-deoxy-3'-thiacytidine or a pharmaceutically acceptable salt thereof.

B1

58. A composition according to claim 57, wherein said composition contains 50-700 mg of said compound β -L-2'-deoxy-3'-thiacytidine or a pharmaceutically acceptable salt thereof.--
